CR-CP Life Sciences led a $77m Series C funding round in MiRXES from CDG Capital and NHH Ventures.

CR-CP Life Sciences, a private equity firm, led a $77m Series C funding round in MiRXES, a Singapore-based early cancer detection diagnostics company, from CDG Capital and NHH Ventures. “We are pleased to welcome Mr. Liu to MiRXES’s Board of Directors as we continue on our exciting journey in delivering early, actionable and personalized diagnoses across the care continuum to save and improve lives. MiRXES is a global organization and Mr. Liu brings international business perspective and leadership to our efforts in creating breakthroughs and expanding MiRXES’s footprint across the globe in cancer early detection and precision medicine,” Dr. Lihan ZHOU, MiRXES Co-Founder and CEO.